Get started
AC Immune SAAC Immune SAAC Immune SA

AC Immune SA

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsETFs

IMR chart


Full chart

IMR upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪241.00 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.49 EUR
Net income (FY)
‪−55.85 M‬ EUR
Revenue (FY)
‪29.95 M‬ EUR
Shares float
‪61.06 M‬
Beta (1Y)
1.50

Employees


Employees (FY)
172
Change (1Y)
+11 +6.83%
Revenue / Employee (1Y)
‪174.15 K‬ EUR
Net income / Employee (1Y)
‪−324.70 K‬ EUR

About AC Immune SA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Andrea Pfeifer
Website
acimmune.com
Headquarters
Lausanne
Founded
2003
ISIN
CH0329023102
FIGI
BBG00W907GL3
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Check out other big names from the same industry as IMR.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IMR news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IMR is 2.50 EUR — it has decreased by −3.78% in the past 24 hours. Watch AC Immune SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange AC Immune SA stocks are traded under the ticker IMR.
IMR stock has risen by 9.01% compared to the previous week, the month change is a 37.34% rise, over the last year AC Immune SA has showed a −23.93% decrease.
We've gathered analysts' opinions on AC Immune SA future price: according to them, IMR price has a max estimate of 10.36 EUR and a min estimate of 6.82 EUR. Watch IMR chart and read a more detailed AC Immune SA stock forecast: see what analysts think of AC Immune SA and suggest that you do with its stocks.
IMR reached its all-time high on Aug 31, 2021 with the price of 11.08 EUR, and its all-time low was 1.28 EUR and was reached on Apr 22, 2025. View more price dynamics on IMR chart.
See other stocks reaching their highest and lowest prices.
IMR stock is 5.05% volatile and has beta coefficient of 1.50. Track AC Immune SA stock price on the chart and check out the list of the most volatile stocks — is AC Immune SA there?
Today AC Immune SA has the market capitalization of ‪240.16 M‬, it has increased by 2.65% over the last week.
Yes, you can track AC Immune SA financials in yearly and quarterly reports right on TradingView.
AC Immune SA is going to release the next earnings report on Nov 14, 2025. Keep track of upcoming events with our Earnings Calendar.
IMR earnings for the last quarter are −0.22 EUR per share, whereas the estimation was −0.22 EUR resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.20 EUR per share. See more details about AC Immune SA earnings.
AC Immune SA revenue for the last quarter amounts to ‪1.40 M‬ EUR, despite the estimated figure of ‪1.40 M‬ EUR. In the next quarter, revenue is expected to reach ‪863.03 K‬ EUR.
IMR net income for the last quarter is ‪−21.78 M‬ EUR, while the quarter before that showed ‪−19.57 M‬ EUR of net income which accounts for −11.30% change. Track more AC Immune SA financial stats to get the full picture.
No, IMR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 29, 2025, the company has 172 employees. See our rating of the largest employees — is AC Immune SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AC Immune SA EBITDA is ‪−46.92 M‬ EUR, and current EBITDA margin is −184.40%. See more stats in AC Immune SA financial statements.
Like other stocks, IMR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AC Immune SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AC Immune SA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AC Immune SA stock shows the neutral signal. See more of AC Immune SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.